I have spent so much time looking into CHM IP that I really have not spent enough time on the management team.
Have a good look at CHM, CEO, Jennifer Chow, what a gun, perfect for CHM.Jennifer Chow is the Chief Executive Officer and Managing Director of Chimeric Therapeutics. Jennifer is a cell therapy pioneer and expert with experience developing and commercializing FDA approved CAR T cell therapies, Abecma™, Breyzani™, Yescarta™ and Tecartus™. Jennifer also has experience leading the commercial development for more than 15 pipeline cell therapies.
Jennifer joined Chimeric from Kite Pharmaceuticals where she was the Head of Global Marketing, Analytics and Commercial Operations and was responsible for optimizing the commercial development of all Kite pipeline therapies.
Prior to Kite, Jennifer was the Global Cell Therapy Commercial Lead at Celgene Corporation defining the global commercial strategy and operating model for Celgene cell therapies.
Jennifer has developed over 10 oncology therapeutics for launch and has more than 20 years’ experience in the biotech and pharmaceutical field.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $20.21K | 5.053M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2213046 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 13563373 | 20 |
View Market Depth
| Last trade - 15.01pm 24/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |